| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Veronicastroside targets multiple pathways, including apoptosis, bacterial targets (such as alginate secretion protein AlgE), and xanthine oxidase. It inhibits xanthine oxidase, an enzyme involved in uric acid production, with an IC50 of 37.4 µg/mL. It also inhibits alginate secretion protein (AlgE) and has activity against Pseudomonas aeruginosa.
|
|---|---|
| ln Vitro |
In vitro, Veronicastroside inhibits xanthine oxidase with an IC50 of 37.4 µg/mL. It inhibits alginate secretion protein (AlgE). It has anti-inflammatory and antioxidant activities, as well as antibacterial effects.
|
| ln Vivo |
In vivo, Veronicastroside has anti-inflammatory, anti-arthritic, and neuroprotective effects. It prevents LPS-induced acute lung injury by inhibiting inflammation and apoptosis. It has antioxidant activity.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for Veronicastroside involve measuring xanthine oxidase activity. The enzyme is incubated with xanthine as a substrate and varying concentrations of Veronicastroside. The production of uric acid is measured spectrophotometrically, and the IC50 for inhibition is calculated.
|
| Cell Assay |
In vitro cell-based experiments for Veronicastroside are conducted using various cell lines. Cells are treated with Veronicastroside and then stimulated with LPS or other inflammatory agents. Inflammatory cytokine levels, apoptosis markers, and oxidative stress are assessed. Antibacterial activity is tested against Pseudomonas aeruginosa.
|
| Animal Protocol |
In vivo animal experiments for Veronicastroside are performed in models of acute lung injury, arthritis, and other inflammatory conditions. Veronicastroside is administered, and inflammation, apoptosis, and tissue damage are assessed.
|
| ADME/Pharmacokinetics |
Veronicastroside is a natural product. Its pharmacokinetic properties are typical of flavonoids, with oral bioavailability and systemic exposure.
|
| Toxicity/Toxicokinetics |
Veronicastroside is well-tolerated in preclinical studies. No significant toxicity has been reported.
|
| References |
|
| Additional Infomation |
Luteolin 7-O-neohesperidin is a disaccharide derivative with the 7-position luteolin replaced by a 2-O-(α-L-rhamnosyl)-β-D-glucopyranosyl glycoside via a glycosidic bond. It possesses antibacterial activity and is also a metabolite. It is a neohesperidin, disaccharide derivative, glycosyloxyflavonoid, and trihydroxyflavonoid. Its function is related to luteolin.
Lonicera japonica has been reported in Biebersteinia multifida, Trachelospermum asiaticum, and other organisms with relevant data. See also: Artichoke leaf (partial). Veronicastroside is also known as Lonicerin. It is a research compound with diverse biological activities. It is not approved for clinical use. |
| Molecular Formula |
C27H30O15
|
|---|---|
| Molecular Weight |
594.52
|
| Exact Mass |
594.158
|
| CAS # |
25694-72-8
|
| PubChem CID |
5282152
|
| Appearance |
Light yellow to yellow solid powder
|
| Vapour Pressure |
0mmHg at 25°C
|
| LogP |
-0.6
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
42
|
| Complexity |
979
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC(=C(C=C5)O)O)O)CO)O)O)O)O)O
|
| InChi Key |
SHPPXMGVUDNKLV-KMFFXDMSSA-N
|
| InChi Code |
InChI=1S/C27H30O15/c1-9-20(33)22(35)24(37)26(38-9)42-25-23(36)21(34)18(8-28)41-27(25)39-11-5-14(31)19-15(32)7-16(40-17(19)6-11)10-2-3-12(29)13(30)4-10/h2-7,9,18,20-31,33-37H,8H2,1H3/t9-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1
|
| Chemical Name |
7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2-(3,4-dihydroxyphenyl)-5-hydroxychromen-4-one
|
| Synonyms |
Scolymoside; Lonicerin; Veronicastroside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~42.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6820 mL | 8.4101 mL | 16.8203 mL | |
| 5 mM | 0.3364 mL | 1.6820 mL | 3.3641 mL | |
| 10 mM | 0.1682 mL | 0.8410 mL | 1.6820 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
